Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2021 | NERO trial: PARP inhibitors for chemosensitive NSCLC

Dean Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, shares an update on the randomized Phase II/III NERO study (NCT01788332) investigating PARP inhibitors in patients with non-small cell lung cancer (NSCLC) who have previously responded to chemotherapy. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.